Sponsor

3M

Clinical research sponsor

Published trials9
Recruiting shown0
Roles2
SourceClinicalTrials.gov

Clinical trials

9 shown
Clinical Evaluation of the SNaP Wound Care SystemNCT01113658 · lead sponsor · 2010-03-01
WITHDRAWN
A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, AdjuvantedNCT05983874 · collaborator · 2024-04-16
UNKNOWN
ABTHERA ADVANCE™ Use Without Wittman PatchNCT04986943 · collaborator · 2020-10-12
COMPLETED
Preventing Adverse Incisional Outcomes at Cesarean Multicenter TrialNCT03009110 · collaborator · 2017-02-08
TERMINATED
Auscultate Obese Patients Using Electronic and Traditional StethoscopesNCT01665820 · collaborator · 2012-10-01
COMPLETED
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy SystemNCT01623882 · collaborator · 2012-06-01
WITHDRAWN
Peritoneal Vacuum Therapy to Reduce Inflammatory Response From Abdominal Sepsis/InjuryNCT01355094 · collaborator · 2011-06-01
COMPLETED
A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot UlcersNCT01013792 · collaborator · 2009-11-01
TERMINATED
Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") CreamNCT00193908 · collaborator · 2004-03-01
COMPLETED

Sponsor roles

collaborator8
lead sponsor1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.